clavaseptin 250 mg tabl.
vétoquinol sa-nv - amoxicillin trihydrate - eq. amoxicillin 200 mg; clavulanic acid 50 mg - tablet - 250 mg - clavulanic acid 50 mg; amoxicillin trihydrate - amoxicillin - dog
clavobay 250 mg tabl. jar
norbrook laboratories (ireland) ltd. - amoxicillin trihydrate - eq. amoxicillin 200 mg; clavulanic acid 50 mg - tablet - 250 mg - clavulanic acid 50 mg; amoxicillin trihydrate - amoxicillin - dog
kesium 200 mg - 50 mg chewable tabl.
ceva santé animale sa-nv - amoxicillin trihydrate - eq. amoxicillin 200 mg; potassium clavulanate - eq. clavulanic acid 50 mg - chewable tablet - 200 mg - 50 mg - clavulanic acid 50 mg; amoxicillin trihydrate - amoxicillin - dog
noroclav 250 mg 200 mg - 50 mg tabl. jar
norbrook laboratories (ireland) ltd. - amoxicillin trihydrate - eq. amoxicillin 200 mg; clavulanic acid 50 mg - tablet - 200 mg - 50 mg - amoxicillin trihydrate; clavulanic acid 50 mg - amoxicillin - dog
amoxicillin/clavulanic acid aurobindo 875mg/125mg film-coated tablets
aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - amoxicillin, clavulanic acid - film-coated tablet - amoxicillin 875 mg clavulanic acid 125 mg - antibacterials for systemic use
amoxicillin/clavulanic acid aptapharma 1000 mg/200 mg powder for solution for injection/infusion
apta medica internacional d.o.o likozarjeva ulica 6, 1000 ljubljana, , slovenia - amoxicillin, clavulanic acid - powder for solution for infusion or injection - amoxicillin 1000 mg clavulanic acid 200 mg - antibacterials for systemic use
amoxicillin/clavulanic acid krka 500 mg/125 mg film-coated tablets
krka, d.d., novo mesto - amoxicillin; clavulanic acid - film-coated tablet - 500 mg/ 125 milligram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; amoxicillin and enzyme inhibitor - : antibacterials for systemic use, combinations of penicillins, incl. beta-lactamase inhibitors - - acute bacterial sinusitis (adequately diagnosed) - acute otitis media - acute exacerbations of chronic bronchitis (adequately diagnosed) - community acquired pneumonia - cystitis - pyelonephritis - skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis. - bone and joint infections, in particular osteomyelitis.
moxiclav duo forte 875/125 amoxicillin trihydrate 875mg and clavulanic acid 125mg tablet blister pack
southern cross pharma pty ltd - amoxicillin trihydrate,potassium clavulanate -
moxiclav duo 500/125 amoxicillin trihydrate 500mg and clavulanic acid 125mg tablet blister pack
southern cross pharma pty ltd - amoxicillin trihydrate,potassium clavulanate -
apx-amoxicillin/clavulanic acid 875/125 amoxicillin 875 mg (as trihydrate) and clavulanic acid 125 mg (as potassium) tablet strip pack
arrotex pharmaceuticals pty ltd - amoxicillin trihydrate, quantity: 1005 mg (equivalent: amoxicillin, qty 875 mg); potassium clavulanate, quantity: 149 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; purified talc; povidone; silicon dioxide; triethyl citrate; hypromellose; titanium dioxide; ethylcellulose - short-term treatment of bacterial infection at the following sites when caused by amoxycillin/clavulanic acid sensitive, beta-lactamase producing organisms. skin and skin structure infections. urinary tract infections (uncomplicated and complicated). upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis. lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to apx-amoxicillin/clavulanic acid 875/125 tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in the microbiological section, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to apx-amoxicillin/clavulanic acid 875/125 tablets should not require the addition of another antibiotic due to the amoxycillin content of apx-amoxicillin/clavulanic acid 875/125 tablets. short-term treatment of bacterial infection at the following sites when caused by amoxycillin/clavulanic acid sensitive, beta-lactamase producing organisms. skin and skin structure infections. urinary tract infections (uncomplicated and complicated). upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis. lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to curam/muric tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in the microbiological section, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to curam/muric tablets should not require the addition of another antibiotic due to the amoxycillin content of curam/muric tablets.